- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Dynamic Contrast-Enhanced CT Detects More Colorectal Liver Metastasis
The contrast-enhanced CT also improves lesion conspicuity over standard care of monophasic portovenous CT.
Dynamic contrast-enhanced CT increased the detection of colorectal liver metastasis, especially for lesions smaller than 15 mm, according to a study published in the European Journal of Radiology.
Researchers from Belgium performed a prospective study to evaluate a dynamic contrast-enhanced CT-protocol and compare this method with standard of care monophasic portovenous CT for detection of colorectal liver metastases.
Related article: Dynamic Contrast-Enhanced, Susceptibility Contrast MR Images Help Grade Gliomas
A total of 135 treatment-naïve patients participated in the study. All underwent dynamic contrast-enhanced CT, followed by routine monophasic portovenous CT of thorax-abdomen-pelvis. Forty-two of the patients presented with liver metastasis. The number and lesion conspicuity of detected liver metastasis on dynamic contrast-enhanced CT using perfusion maps was compared to monophasic CT.
The results showed that dynamic contrast-enhanced CT outperformed portovenous CT for detection as well as conspicuity of colorectal liver metastasis, at a relatively low dose increment.
The researchers concluded that using dynamic contrast-enhanced CT increased the detection of colorectal liver metastasis, especially for lesions smaller than 15 mm, when compared to monophasic portovenous CT. Dynamic contrast-enhanced CT also has the added advantage of improved lesion conspicuity, which can positively influence reader confidence and clinical workflow.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
